Spotlight on ixazomib: potential in the treatment of multiple myeloma

References

• CottiniFAndersonKNovel therapeutic targets in multiple myelomaClin Adv Hematol Oncol201513423624826352582
   PubMedGoogle Scholar
• Karp LeafRChoHJAviganDImmunotherapy for multiple myeloma, past, present, and future: monoclonal antibodies, vaccines, and cellular therapiesCurr Hematol Malig Rep Epub201594
   PubMed Web of Science ®Google Scholar
• GentileMRecchiaAGMazzoneCEmerging biological insights and novel treatment strategies in multiple myelomaExpert Opin Emerg Drugs201217340743822920042
   PubMed Web of Science ®Google Scholar
• MoreauPTouzeauCMultiple myeloma: from front-line to relapsed therapiesAm Soc Clin Oncol Educ Book201535e504e51125993216
   PubMedGoogle Scholar
• de la PuentePAzabAKContemporary drug therapies for multiple myelomaDrugs Today (Barc)201349956357324086952
   PubMed Web of Science ®Google Scholar
• de la PuentePMuzBAzabFMolecularly targeted therapies in multiple myelomaLeuk Res Treatment2014201497656724829804
   PubMedGoogle Scholar
• KumarSKLaPlantBRoyVPhase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibBlood Cancer J20154e33826275080
   PubMed Web of Science ®Google Scholar
• DouQPZonderJAOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome systemCurr Cancer Drug Targets201414651753625092212
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyLancet Oncol201112543144021507715
   PubMed Web of Science ®Google Scholar
• ArnulfBPylypenkoHGrosickiSUpdated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myelomaHaematologica201297121925192822689676
   PubMed Web of Science ®Google Scholar
• LokAMocquardJBourcierJSubcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myelomaHaematologica2014993e33e3424532044
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 studyHaematologica20151005e207e21025596270
   PubMed Web of Science ®Google Scholar
• WangLWangKFChangBYOnce-weekly subcutaneous administration of bortezomib in patients with multiple myelomaAsian Pac J Cancer Prev20151652093209825773856
   PubMedGoogle Scholar
• SteeleJMCarfilzomib: a new proteasome inhibitor for relapsed or refractory multiple myelomaJ Oncol Pharm Pract201319434835423292972
   PubMedGoogle Scholar
• BuacDShenMSchmittSFrom bortezomib to other inhibitors of the proteasome and beyondCurr Pharm Des201319224025403823181572
   PubMed Web of Science ®Google Scholar
• AoLWuYKimDDevelopment of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomibMol Pharm2012982197220522734651
   PubMedGoogle Scholar
• AbrahamJSalamaNNAzabAKThe role of P-glycoprotein in drug resistance in multiple myelomaLeuk Lymphoma2015561263324678978
   PubMed Web of Science ®Google Scholar
• RumpoldHSalvadorCWolfAMKnockdown of PgP resen-sitizes leukemic cells to proteasome inhibitorsBiochem Biophys Res Commun2007361254955417662692
   PubMed Web of Science ®Google Scholar
• RichardsonPGBazRWangMPhase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsBlood201412471038104624920586
   PubMed Web of Science ®Google Scholar
• ChauhanDTianZZouBIn vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cellsClin Cancer Res201117165311532121724551
   PubMed Web of Science ®Google Scholar
• OffidaniMCorvattaLCaraffaPAn evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myelomaOncoTargets Ther2014717931800
   PubMed Web of Science ®Google Scholar
• KuppermanELeeECCaoYEvaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancerCancer Res20107051970198020160034
   PubMed Web of Science ®Google Scholar
• LednicerDAntineoplastic Drugs: Organic SynthesesChichesterWiley2015
   Google Scholar
• AdamsJBehnkeMChenSPotent and selective inhibitors of the proteasome: dipeptidyl boronic acidsBioorg Med Chem Lett1998843333389871680
   PubMed Web of Science ®Google Scholar
• TouchetSCarreauxFCarboniBAminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitorsChem Soc Rev20114073895391421431144
   PubMed Web of Science ®Google Scholar
• KimKBCrewsCMFrom epoxomicin to carfilzomib: chemistry, biology, and medical outcomesNat Prod Rep201330560060423575525
   PubMed Web of Science ®Google Scholar
• KuhnDJChenQVoorheesPMPotent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood200711093281329017591945
   PubMed Web of Science ®Google Scholar
• KumarSKBerdejaJGNiesvizkyRSafety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyLancet Oncol201415131503151225456369
   PubMed Web of Science ®Google Scholar
• TianZZhaoJJTaiYTInvestigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cellsBlood2012120193958396722983447
   PubMed Web of Science ®Google Scholar
• AzabAKHuJQuangPHypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like featuresBlood2012119245782579422394600
   PubMed Web of Science ®Google Scholar
• KawanoYMoschettaMManierSTargeting the bone marrow microenvironment in multiple myelomaImmunol Rev2015263116017225510276
   PubMed Web of Science ®Google Scholar
• AzabAKRunnelsJMPitsillidesCCXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapyBlood2009113184341435119139079
   PubMed Web of Science ®Google Scholar
• AzabAKSahinIMoschettaMCXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myelomaBlood2014124121905191425079359
   PubMed Web of Science ®Google Scholar
• AzabAKQuangPAzabFP-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironmentBlood201211961468147822096244
   PubMed Web of Science ®Google Scholar
• AzabAKAzabFBlottaSRhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myelomaBlood2009114361962919443661
   PubMed Web of Science ®Google Scholar
• GhobrialIMMyeloma as a model for the process of metastasis: implications for therapyBlood20121201203022535658
   PubMed Web of Science ®Google Scholar
• ToscaniDBolzoniMAccardiFThe osteoblastic niche in the context of multiple myelomaAnn N Y Acad Sci20151335456225424768
   PubMed Web of Science ®Google Scholar
• RoodmanGDPathogenesis of myeloma bone diseaseLeukemia200923343544119039321
   PubMed Web of Science ®Google Scholar
• Garcia-GomezAQuwaiderDCanaveseMPreclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone diseaseClin Cancer Res20142061542155424486586
   PubMed Web of Science ®Google Scholar